

**Question for written answer E-004547/2025
to the Commission**
Rule 144
Nicolás González Casares (S&D)

Subject: Biomedical research affected by disruptions to the EU-US partnership

On 1 May, the United States' National Institutes of Health (NIH) halted all funding for European and non-American teams involved in NIH-financed biomedical research projects with immediate effect. This decision has had major repercussions for the research teams working on NIH-funded transatlantic projects, but its impact is not limited to financial matters: the measure will also undermine the American agency's standing as a global research leader, adversely affect the highly qualified personnel it was funding, disrupt the United States' strategic scientific partnership with the EU and make it impossible to derive any benefit whatsoever from the data that the aforementioned studies (particularly those in the biomedical field, where the cuts have hit the hardest) have collected and analysed.

In the light of the above:

1. Is the Commission planning to implement a contingency plan to sustain and support the research teams affected by the NIH's funding cuts for programmes based in Europe?
2. What action will the Commission take as regards the EU resources that have already been allocated to American research teams and what arrangements will it make concerning American applications to future EU-funded programmes?
3. What steps is the Commission taking to increase cooperation on biomedical research with other countries that provide greater legal certainty?

Submitted: 13.11.2025